Takeda Pharmaceutical Company Limited, accessible via takeda.com, is a global biopharmaceutical firm with a rich history spanning over 240 years. The company is deeply committed to research and development (R&D), focusing on discovering and delivering life-changing treatments and vaccines. Takeda places a strong emphasis on patient-centric values, ensuring that patients' needs are at the forefront of their operations.

Takeda serves a diverse range of clients, including healthcare providers, hospitals, and patients worldwide. The company operates in the biopharmaceutical market, which involves the development and commercialization of drugs and vaccines. This market is highly competitive and requires significant investment in R&D to stay ahead.

The business model of Takeda revolves around the development of new molecular entities (NMEs) and the commercialization of these innovations. They have a robust pipeline with 11 NMEs and aim for up to 15 product launches through FY2024. Takeda partners with approximately 41,000 third-party suppliers globally to source the materials and services necessary for the production and distribution of their medicines.

Takeda generates revenue primarily through the sale of its pharmaceutical products. In FY2020, the company reported underlying revenue growth of 2.2%, driven largely by its 14 global brands. This growth underscores the company's ability to innovate and meet the needs of the market.

In addition to its business operations, Takeda is committed to environmental sustainability. The company recognizes that environmental health is closely linked to human health and is actively working to mitigate environmental risks that could impact public health.

Keywords: Biopharmaceutical, R&D, Patient-Centric, Global Brands, NMEs, Healthcare Providers, Environmental Sustainability, Revenue Growth, Innovation, Long-Term Commitment.